Abstract Library

#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort

Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Beek D

Authors: van Beek D, Verkooijen H, Bonsing B, van Eijck C, van Goor H,

Keywords: Multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, reliability, agreement, computed tomography, magnetic resonance imaging, endoscopic ultrasonography, pathology,

#2996 A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT

Introduction: The number of dosimetry studies after PRRT is increasing, yet different methodologies are used which challenge comparison or pooling of results.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Huizing D, Peters S, Versleijen M, Martens E, Verheij M,

Keywords: dosimetry, PRRT, quantification,

#2986 Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data

Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Gaspar T, Pinheiro J, Canberk S, İnce �, Tokat F,

Keywords: pancreas, pancreatic neuroendocrine tumors, PNETs, ATRX, DAXX, ALT, mosaic,

#2804 Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors

Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wong M, Huynh C, Kim S, Dhall D, Guindi M,

Keywords: claudin-18, anti-claudin 18, neuroendocrine tumor, neuroendocrine hyperplasia, autoimmune metaplastic atrophic gastritis,

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Siebenhüner A

Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,

Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,